Oncolytic viruses are a potential therapeutic approach that uses viruses to selectively infect and kill cancer cells. In a new publication in Cell Reports Medicine, researchers from Heinrich-Heine-Universität Düsseldorf and Abalos Therapeutics GmbH show that tumor-tropic mutations in lymphocytic choriomeningitis virus (LCMV) enhance selective replication in cancer cells.